TRANSFORMING MEDICINE. RESTORING WELLBEING.

DURECT is actively developing new therapeutics based on its Epigenomic Regulator Program and proprietary drug delivery platforms.

DURECT is a biopharmaceutical company focused on the development of medicines that provide meaningful advances in patient health and wellbeing.

INVESTOR RELATIONS >

DURECT's Investor section provides comprehensive information to existing and potential stockholders, including up-to-date stock information, financial reports, investor events and more.

PIPELINE
INVESTORS
PIPELINE : PHASE 1

DUR-928

An endogenous, orally bioavailable small molecule in development for chronic liver disease and acute organ injury.

SEE HOW IT WORKS